Condition
Astrocytoma, IDH-Mutant, Grade 3 clinical trials and research
As of November 12, 2026, Find a Trial lists 4 Astrocytoma, IDH-Mutant, Grade 3 clinical trials that are recruiting, at sites in 3 countries (most in United States (4), Australia (1), China (1)). By phase: Phase 3 (2), Phase 2 (1), Phase 1/2 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 4Clinical trials
- 3Countries
Newest Astrocytoma, IDH-Mutant, Grade 3 clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Safusidenib in IDH1-mutant glioma after vorasidenib progression | Phase 2 | Los Angeles, California and 11 other locations | Recruiting | Jul 14, 2026 |
| Retifanlimab With or Without DFMO for Progressive High-Grade Gliomas | Phase 1/2 | Rochester, Minnesota | Recruiting | Mar 12, 2026 |
| Vor a sid en ib + temozolomide after radiation for IDH-mutant astrocytoma (grade 3) | Phase 3 | Phoenix, Arizona and 176 other locations | Recruiting | Oct 14, 2025 |
| Safusidenib as maintenance therapy for IDH1‑mutant astrocytoma and oligodendroglioma | Phase 3 | Birmingham, Alabama and 60 other locations | Recruiting | Mar 31, 2022 |
All recruiting trials (4)
-
Safusidenib in IDH1-mutant glioma after vorasidenib progression
This trial tests safusidenib in people with IDH1-mutant glioma who progressed on vorasidenib and did not need immediate chemo or radiation.
-
Retifanlimab With or Without DFMO for Progressive High-Grade Gliomas
This trial tests whether retifanlimab, with or without DFMO, is safe and may help treat progressive high-grade gliomas in adults.
-
Vor a sid en ib + temozolomide after radiation for IDH-mutant astrocytoma (grade 3)
This phase 3 trial tests whether adding vorasidenib to the usual temozolomide after radiation helps people with newly diagnosed IDH-mutant astrocytoma (grade 3).
-
Safusidenib as maintenance therapy for IDH1‑mutant astrocytoma and oligodendroglioma
This trial tests whether the oral drug safusidenib can help people with IDH1‑mutant astrocytomas or oligodendrogliomas remain progression‑free longer after surgery and standard radiation/chemotherapy.
Related topics
Quick answers
How many Astrocytoma, IDH-Mutant, Grade 3 clinical trials are recruiting right now?
4, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 3 countries. The most sites are in United States (4 trials), Australia (1 trial), China (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 3: 2, Phase 2: 1, Phase 1/2: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.